Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $28.67 down -1.58% from its previous closing price of $29.13. In other words, the price has decreased by -$1.58 from its previous closing price. On the day, 0.79 million shares were traded. DNLI stock price reached its highest trading level at $29.67 during the session, while it also had its lowest trading level at $28.46.
Ratios:
For a deeper understanding of Denali Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.46 and its Current Ratio is at 12.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 30 ’24 when STEVE KROGNES bought 30,000 shares for $29.43 per share.
SATO VICKI L sold 1,020 shares of DNLI for $30,600 on Sep 13 ’24. The Director now owns 115,156 shares after completing the transaction at $30.00 per share. On Sep 13 ’24, another insider, VICKI LEE SATO, who serves as the Director of the company, bought 6,160 shares for $27.96 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 4104540416 and an Enterprise Value of 3257256192. For the stock, the TTM Price-to-Sale (P/S) ratio is 3231.81 while its Price-to-Book (P/B) ratio in mrq is 2.96. Its current Enterprise Value per Revenue stands at 2570.841 whereas that against EBITDA is -6.585.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $32.13, while it has fallen to a 52-week low of $14.56. The 50-Day Moving Average of the stock is 12.26%, while the 200-Day Moving Average is calculated to be 36.29%.
Shares Statistics:
For the past three months, DNLI has traded an average of 991.11K shares per day and 1009710 over the past ten days. A total of 138.39M shares are outstanding, with a floating share count of 119.08M. Insiders hold about 16.82% of the company’s shares, while institutions hold 84.19% stake in the company. Shares short for DNLI as of 1726185600 were 9397380 with a Short Ratio of 9.48, compared to 1723680000 on 8363326. Therefore, it implies a Short% of Shares Outstanding of 9397380 and a Short% of Float of 7.6899999999999995.
